Boehringer's Ofev shown to slow disease progression in IPF

Pooled analysis from the TOMORROW and INPULSIS trials, recently published in Respiratory Medicine, confirmed that Ofev (nintedanib) reduces the risk of acute exacerbations by approximately 50% in people with idiopathic pulmonary fibrosis (IPF), a rare and serious lung disease, German family-owned pharma major Boehringer Ingelheim announced today.

The findings also showed that Ofev slowed disease progression by approximately 50% across the range of patient types in the clinical trial program and reduced the risk of death.

The pooled analysis is based on data from the Phase II TOMORROW trial and the two Phase III INPULSIS trials that included a total of 1,231 people with IPF (723 treated with Ofev, 508 treated with placebo). A separate meta analysis was conducted to summarize the data from all three trials examining Ofev efficacy and safety. Data from these three clinical trials formed the basis for the approval of Ofev in the USA in 2014, in Europe in 2015, Japan and other countries worldwide.